Per von Mentzer

Per von Mentzer


Roles in PharmNovo: Chief executive officer, member of the Board.

Born: 1960.

Education: Bachelor’s degree in International Business Administration from the University of Lund.

Other current appointments: None.

Work experience: 30 years of experience from International business in various industries and has vast experience in developing and transforming mid-size businesses. In 2003–2007 Per was VP Marketing & Sales for Nybron Flooring, European market leader in parquet flooring, with HQ in Switzerland and during 2008–2017 he was CEO at Elfa International with HQ in Malmö, Sweden.

Holdings: 25 000 shares.

Member of:

Latest news

View all
July 17, 2024

17.5m EUR blended funding from EIC

PharmNovo is very pleased to announce that we have been awarded a 2.5m EUR grant and an opportunity for up to 15m EUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.

Read more
June 5, 2024

PharmNovo presenting at the Global Forum

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.

Read more
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more